Leadership Team

shutterstock_736552108_1

Leadership Team

i-dinkelborg

Ludger Dinkelborg, PhD
Director of the Board, Life Molecular Imaging SA
Member of the Board, Life Molecular Imaging Inc
Managing Director, Life Molecular Imaging GmbH
Director of the Board, Piramal Imaging Ltd

Before joining Life Molecular Imaging, Dr. Dinkelborg served as Managing Director of Piramal Imaging GmbH, as Director of the Board of Piramal Imaging SA and was the Head of Diagnostic Imaging Research at Bayer HealthCare. He brings more than 20 years of R&D experience in the pharmaceutical industry.

He received his PhD in biology at Heinrich-Heine-University, Düsseldorf, Germany and stayed as guest researcher at the Max-Planck-Institute for Molecular Physiology in Dortmund. He became a fellow of the Konrad-Adenauer-Foundation, attended the Cranfield Schering University course for managers, and the Stanford Executive Program, at Stanford School of Business, Stanford, CA.


i-stephens

Andrew Stephens, MD, PhD
Chief Medical Officer

Dr. Stephens has more than 20 years of experience in the pharmaceutical industry, primarily in the areas of neurodegenerative diseases, oncology and diagnostic imaging. Previously, he was Chief Medical Officer at Piramal Imaging and the VP Head Experimental Medicine Oncology/Diagnostic Imaging for Bayer Pharma. He has held positions of increasing responsibility at NeXagen/NeXstar, Gilead, Schering AG, and OSI Pharmaceuticals.

He received his BA cum laude in chemistry from the University of Colorado, Boulder. He also received an MD with honors and a PhD in biochemistry, biophysics and genetics from the University of Colorado, Boulder. Dr. Stephens is Board certified in Internal Medicine and had a clinical practice before entering pharmaceutical development.


Susan-De-Santi

Susan De Santi, PhD
VP, Medical Affairs, North America and Asia Pacific

Dr. Susan De Santi is the VP of Medical Affairs for North America and Asia Pacific with six years of industry experience in diagnostic molecular imaging in both clinical development and Medical Affairs. Previously, she was the Global Medical Director, PET Neurology, Life Sciences, GE Healthcare and the Director, Global Clinical Development in Diagnostic Imaging at Bayer Healthcare Pharmaceuticals.

Susan was the 2015 Chairperson for the Private Partner Scientific Board of The Alzheimer’s Disease Neuroimaging Initiative (ADNI) and represents the interest of Piramal Imaging in other Alzheimer and Dementia Initiatives. She is a member of SNMMI and is on the Board of Directors of the Public Health Foundation Enterprises. Susan has co- authored more than 60 peer-reviewed articles, 10 book chapters and co-edited 1 book.

Prior to joining Life Molecular Imaging and Piramal, Susan was an Associate Professor in the Department of Psychiatry, at New York University Langone Medical Center. In addition she was the Administrative Director at the Center for Brain Health and retains an adjunct Associate Professorship at this institution. She received her PhD from The Graduate School and University Center of CUNY with an emphasis in Neurolinguistics. Susan’s research focused on early diagnostic markers of mild cognitive impairment and Alzheimer’s disease using brain imaging (MRI, FDG and amyloid PET), biological markers, and cognition.


william-f-abbott

William F. Abbott
VP of Commercial Operations, North America and International

William F. Abbott is the Vice President, Operations for Life Molecular Imaging with overall accountability for commercial operations in the Americas.

Mr. Abbott has over thirty years of molecular imaging agent and device experience. He worked for DuPont Pharma (now Lantheus Medical Imaging) for 23 years serving in a diverse number of upper level management positions with responsibilities spanning manufacturing, customer service, distribution, marketing and business development functions. During his five-year tenure at Bracco Diagnostics, Inc. he served as Vice President of Operations and General Manager of Nuclear Medicine and was instrumental in repositioning Rb-82 as a clinically relevant myocardial perfusion imaging agent. As President of Jubilant Draximage, he served as chief executive officer of a $30M radiopharmaceuticals business directing all aspects of the business directing its aggressive global organic growth strategy and pipeline development of five concurrent projects.

Mr. Abbott has also served as chairmen of the board for Cardiac Imaging Solutions, CEO of a drug delivery platform start-up business and founded his own consulting business serving various clients within the molecular imaging industry.


nico

Nico Beukman
VP of Commercial Operations, Northern Europe

Nico Beukman is the VP of Commercial Operations, Northern Europe at Piramal Imaging Ltd, and has served as the Director and Secretary to the Board of Piramal Imaging Limited for the past two years.

Mr. Beukman has more than 20 years of experience in the medical industry with a proven track record for managing strategic growth and execution of sales, marketing and commercial activities. Throughout his career, he has implemented creative and effective solutions for driving revenue growth and improving profitability while managing multinational teams.

Prior to Life Molecular Imaging and Piramal Imaging, Mr. Beukman spent twelve years at Covidien now Mallinckrodt serving the company in various roles. Most recently, Mr. Beukman was the Vice President of Marketing for Pharmaceuticals and Imaging Solutions at Covidien. He was responsible for all marketing activities for sales in Europe, the Middle East and Africa for contrast media, devices, consumables and nuclear medicine product portfolios. Mr. Beukman earned his diploma in Clinical Engineering at Tswane University of Technology in South Africa.